IA SF233

Expands Iowa's "Right to Try Act" to include patients with life-threatening or severely debilitating illnesses, not just terminal illnesses, allowing them to access investigational drugs, biological products, devices, or individualized investigational treatments

Defines "individualized investigational treatment" as treatments unique to a specific patient based on their genetic profile, including gene therapy, antisense oligonucleotides, and neoantigen vaccines

Adds "eligible facility" definition for institutions operating under federalwide assurance for human subjects protection, allowing manufacturers within such facilities to provide investigational treatments

Requires detailed written informed consent including explanations of approved treatments, potential outcomes, patient liability for expenses, and statements about health plan coverage limitations and hospice eligibility impacts

Protects physicians from license revocation and manufacturers/facilities from liability when acting in good faith under the chapter, while prohibiting state officials from blocking eligible patients' access to investigational treatments